Glasgow (PRWEB) July 01, 2013
AB SCIEX, Genedata, and LECO announce a technology partnership that will deliver a collaborative software system, which will enable metabolomics researchers to comprehensively process and analyze experimental data across different GC/MS and LC/MS platforms. LECO Corporation, a global leader in accurate mass technologies and GC/MS instrumentation, is offering combined solutions with both AB SCIEX, a global leader in LC/MS technology, and Genedata, a global leader in advanced software solutions for drug discovery and life science research. The companies are collaborating to provide a seamless solution to extract valuable biological information from high fidelity LC and GC data. The solution will give metabolomics researchers the ultimate tool for truly comprehensive metabolomics investigations. The partnership announcement was made at the 9th Annual Conference of the Metabolomics Society (July 1-4).
“The ability to bring data from different vendors and technologies onto a single platform, which can process and merge data for maximum biological inference, is where the industry needs to be to effectively evaluate the entire metabolome,” said Dr. Vladimir V. Tolstikov, Scientist, Tailored Therapeutics of Eli Lilly and Company.
The close collaboration of the three companies has resulted in the latest version of Genedata Expressionist® MSX software, developed for metabolomics experiments performed with LECO and AB SCIEX MS systems. Genedata Expressionist MSX, which is compatible with other data formats and technologies as well, is a comprehensive, end-to-end solution for the analysis of mass spectrometry data generated in metabolomics experiments. The software can be downloaded directly via the Internet for immediate installation.
About AB SCIEX
AB SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to push the limits in their field and address the complex analytical challenges they face. The company’s global leadership and world-class service and support in the mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics, and clinical research. With 30 years of proven innovation, AB SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive, and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information about the company, go to http://www.absciex.com. Follow AB SCIEX on Twitter (@ABSCIEX), and LinkedIn.
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies, as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. For more information, visit http://www.expressionist-msx.com or http://www.genedata.com.
About LECO Corporation
For over 75 years, industries around the world have trusted LECO Corporation to deliver technologically advanced products and solutions. Today, that commitment continues with high-speed/high resolution Time-of-Flight Mass Spectrometry (TOFMS) as well as comprehensive two-dimensional gas chromatography (GCxGC), all featuring easy-to-use ChromaTOF® operating software. Product lines also include high-quality analytical instrumentation, metallography and optical equipment, and consumables. LECO currently has over 30 subsidiaries worldwide, in countries such as the United Kingdom, Australia, Sweden, Canada, and Mexico, with additional distributors authorized to sell or service LECO products to the rest of the world. For more information, visit http://www.leco.com, or follow us on Twitter (@LECOCorp), and LinkedIn.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.